Progenitor was born on the Matisse™ Reprogramming System technology for the generation of highly pluripoptent induced pluripotent stem cells. Using this technology, progenitor developed methods for immune cell differentiation, sparking their interest in the Cellular Immunotherapy.
Scientists have discovered new methods for cancer cell targeting using chimeric antigen receptor (CAR) constructs, that when paired with the body’s killing immune cells, can be a potent therapy for previously immuno-evasive cancers.
A major challenge for CAR-cell therapies in the clinic is their complexity and cost: present technology requires that primary immune cells be isolated and subjected to extensive in vitro engineering on a patient-by- patient basis, costing up to $500,000 per treatment per patient; hence routine clinical use of these therapies is potentially unfeasible in the current healthcare economy.
Seeing Immunotherapy’s need for an enhanced workflow, Progenitor set a goal to create IP for the generation of safer, economical and more advanced cellular therapeutics.
Through partnerships and collaborations, Progenitor has created a novel workflow covering all aspects of cellular therapeutic generation. Using next generation CAR constructs, gene editing techniques and “Off-the-shelf” approaches, Progenitor is enabling the future of Immunotherapies.